PetVivo (PETV) 10-K/A 14 Nov 18 2017 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2017	Dec. 04, 2017
Document And Entity Information
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	1,512,922
Document Type	10-K/A
Document Period End Date	Mar. 31, 2017
Amendment Flag	true
Amendment Description	This Amendment No. 3 to the Registrant's Annual Report on Form 10-K for its fiscal year ended March 31, 2017 is being filed solely to include the audited financial statements required by Item 8, which were mistakenly omitted in the Amendment No. 2 of the same.
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float	$ 30,577,083
Entity Common Stock, Shares Outstanding		16,689,334
Trading Symbol	PETV
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Current Assets
Cash and cash equivalents	$ 25,434	$ 258
Accounts receivable	163
Employee advance		15,900
Prepaids	8,590	19,121
Total Current Assets	34,187	35,279
Property and Equipment:
Property & equipment	103,503	103,504
Less: accumulated depreciation	(103,054)	(102,694)
Total Fixed Assets	449	810
Other Assets:
Goodwill		13,407,693
Trademark and patents-net	1,862,301	3,245,662
Total Other Assets	1,862,301	16,653,355
Total Assets	1,896,937	16,689,444
Current Liabilities
Accounts payable & accrued expenses	643,890	1,063,538
Note payable and accrued interest-related party	197,055	193,370
Notes payable and line of credit loan	131,247	165,849
Convertible notes payable, net of discount of $0 and $3,311 at March 31, 2017 and March 31, 2016, respectively	105,000	31,689
Derivative liability		24,460
Total Current Liabilities	1,077,192	1,478,906
Commitments and Contingencies
Stockholders' Equity:
Common stock, par value $0.001, 250,000,000 shares authorized, issued 9,321,306 and 7,931,639 shares outstanding at March 31, 2017 and 2016	9,322	7,931
Common stock to be issued	1,349,919	1,576,649
Additional Paid-In Capital	30,567,761	28,224,376
Accumulated Deficit	(45,410,816)	(29,879,283)
Total PetVivo Stockholders' (Deficit) Equity	(13,483,814)	(70,327)
Non-Controlling Interest	14,303,559	15,280,865
Total Stockholders' Equity	819,745	15,210,538
Total Liabilities and Stockholders' (Deficit) Equity	$ 1,896,937	$ 16,689,444

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Statement of Financial Position [Abstract]
Convertible notes payable, discount	$ 0	$ 3,311
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	9,321,306	7,931,639
Common stock, shares outstanding	9,321,306	7,931,639

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Revenues	$ 7,124	$ 75,000
Cost of Sales
Gross Profit	7,124	75,000
Operating Expenses:
Research and Development	167,891	168,600
General and Administration	16,228,886	3,157,583
Total Operating Expenses	16,396,777	3,326,183
Operating Loss	(16,389,653)	(3,251,183)
Other Income (Expense)
Gain (Loss) on Settlement of Debt	24,460	(382,296)
Sale of Equipment	32,000
Change in Fair Value of Derivatives		165,444
Interest Expense	(188,505)	(270,582)
Amortization of Issue Costs		(992,180)
Total Other Expense	(132,045)	(1,479,614)
Net Income (Loss) before taxes	(16,521,698)	(4,730,797)
Income Tax Provision
Net Income (Loss)	(16,521,698)	(4,730,797)
Net Loss Attributable To Non-Controlling Interest	990,165	1,079,053
Net loss attributable to PetVivo	$ (15,531,533)	$ (3,651,744)
Net Income (Loss) Per Share - Basics And Diluted	$ (1.73)	$ (0.46)
Weighted Average Common Shares Outstanding - Basic And Diluted	8,955,222	7,853,862

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Stock to be Issued [Member]	Total
Balance at Mar. 31, 2015	$ 7,700	$ 26,381,094	$ (26,227,539)			$ 161,255
Balance, shares at Mar. 31, 2015	7,700,289
Non-Controlling interest				16,683,000		16,683,000
Common stock issued for cash	$ 10	37,090				37,100
Common stock issued for cash, shares	10,600
Common stock issued for services	$ 149	555,101				555,250
Common stock issued for services, shares	149,000
Common shares issued to settle liabilities	$ 71	281,929				282,000
Common shares issued to settle liabilities, shares	70,500
Issuance of Gel Del Preferred stock for cash				100,005		100,005
Stock issued to extend debt	$ 1	4,349				4,350
Stock issued to extend debt, shares	1,250
Write off of preacquisition liabilities				(423,282)		(423,282)
Exercise of Gel Del options				195		195
Settlement of derivative liabilities		427,870				427,870
Stock to be issued for conversion of debt					1,576,649	1,576,649
Inducement to convert debt		536,943				536,943
Stock issued for interest
Net loss			(3,651,744)	(1,079,053)		(4,730,797)
Balance at Mar. 31, 2016	$ 7,931	28,224,376	(29,879,283)	15,280,865	1,576,649	15,210,538
Balance, shares at Mar. 31, 2016	7,931,639
Common stock issued for cash	$ 67	99,684				99,751
Common stock issued for cash, shares	66,500
Common stock issued for services	$ 438	382,062				382,500
Common stock issued for services, shares	437,500
Stock issued to reduce debt	$ 789	1,575,860			(1,576,649)
Stock issued to reduce debt, shares	788,325
Stock to be issued					1,349,919	1,349,919
Stock issued for interest	$ 97	151,379				151,476
Stock issued for interest, shares	97,342
Stock issued for services-Gel-Del				12,859		12,859
Warrants issued for services		134,400				134,400
Net loss			(15,531,533)	(990,165)		(16,521,698)
Balance at Mar. 31, 2017	$ 9,322	$ 30,567,761	$ (45,410,816)	$ 14,303,559	$ 1,349,919	$ 819,745
Balance, shares at Mar. 31, 2017	9,321,306

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss) For The Period	$ (16,521,698)	$ (4,730,797)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash consulting expense	134,400
Stock issued for services	395,359	555,250
Stock issued for interest	151,476
Stock issued to settle liabilities	1,289,921	282,000
Depreciation and amortization	746,845	743,631
Amortization of debt issue costs		992,180
Loss of sale of Gel-Del & Cosmeta	14,081,031
Derivative (gain) or loss adjustment		(165,444)
Forgiveness of debt	(24,460)	382,296
License		488,000
Changes in Operating Assets and Liabilities
Decrease in prepaid expense and employee advances	26,431	215,500
Increase in advances and receivables	(163)	(15,900)
Increase in accounts payable and accrued expense	(425,470)	562,954
Net Cash Used in Operating Activities	(143,017)	(690,330)
CASH FLOWS FROM INVESTING ACTVITITES
Increase in patent costs	(36,465)
Net Cash Used in Investing Activities	(36,465)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock sale	99,750	137,105
Increase in notes to related parties	1,230
Proceeds from convertible notes	105,000	524,750
Proceeds from notes payable	12,500	193,370
Cash received from common stock subscription	60,000
Repayments of convertible notes	(35,000)
Repayments of loans and line of credit	(38,822)	(204,500)
Net Cash Provided by Financing Activities	204,658	650,725
Net (Decrease) Increase in Cash	25,176	(39,605)
Cash at Beginning of Period	258	39,863
Cash at End of Period	25,434	258
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During The Year For: Interest
Cash Paid During The Year For: Income taxes paid
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Shares issued as payment of note payable		1,362,246
Shares issued as payment for accrued salaries	$ 1,209,919	$ 282,000

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	12 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. PetVivo Inc. was originally incorporated under the laws of the state of Minnesota on August 1, 2013.The financials are the result of a merger between Technologies Scan Corp., a corporation incorporated in the State of Nevada on March 31, 2009 now known as PetVivo Holdings, Inc. and its subsidiaries, PetVivo Inc., Gel-Del Technologies, Inc., and Cosmeta Corp. (collectively the “Company”). For accounting purposes the Company is treating the merger as a reverse merger whereby the consolidated financials presented are those of the surviving entity that, which is PetVivo. The merger occurred on March 14, 2014. PetVivo is in the business of distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals. On April 10, 2015 the Company agreed to acquire Gel-Del Technologies. The Company consummated the merger with Gel-Del Technologies, Inc. on April 10, 2017 through an Agreement and Plan of Merger as explained in Note 7. The issuance of the shares to complete the transaction has been finalized and the financials presented are those of the consolidated entities under common control. (B) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of PetVivo Holdings, Inc. and its wholly owned operating subsidiary, PetVivo Inc. as well as its variable interest entity (VIE) Gel-Del Technologies and its subsidiary Cosmeta Inc. All intercompany accounts have been eliminated upon consolidation. The consolidation including the VIE is included due to the fact that the Company controls the entity as well as the fact an agreement for acquisition has occurred. The accounting for the acquisition of Gel-Del Technologies on April 10, 2017 was as follows: The Company will issue 5,450,000 shares valued at market at $0.40 per share, which equaled $2,180,000 on the date of closing. The assets of Gel-Del equaled $295,716 and its liabilities were $2,295,462 or a difference of $1,999,746 that resulted in a total purchase consideration of $4,179,746, which was allocated between goodwill and the value of patents & trademarks. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (D) Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2017 and March 31, 2016, the Company had no cash equivalents. (E) Concentration-Risk The Company maintains its cash with various financial institutions, which may exceed federally insured limits throughout the period. (F) Machinery & Equipment Machinery and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of furniture fixtures and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful life of three (3) years for equipment, five (5) years for automobile, and seven (7) years for furniture and fixtures. Upon sale or retirement of computer equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations. (G) Patents and Trademarks The Company capitalizes direct costs for their maintenance and advancement of their patents and trademarks and amortizes these costs over a useful life of 60 months. (H) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company adopted the provisions of ASC Topic 740, on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with Statement of Financial Accounting Standards No. 5, Accounting for Contingencies. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (I) Loss Per Share In accordance with the accounting guidance now codified as FASB ASC Topic 260, “Earnings per Share” basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. (J) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 605, “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. Revenues consist of Kush product sales to veterinary clinics. (K) Research and Development The Company expenses research and development costs as incurred. (L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts payable, accrued expenses, notes payable, notes payable - related party, loan payable - related party and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of March 31, 2017 and March 31, 2016, due to the short-term nature of these instruments. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The following table represents the Company’s assets and liabilities by level measured at fair value on a recurring basis at March 31, 2017: Description Level 1 Level 2 Level 3 Notes payable at fair value $ $ $ The following assets and liabilities are measured on the condensed consolidated balance sheets at fair value on a recurring basis utilizing significant unobservable inputs or Level 3 assumptions in their valuation. The following tables provide a reconciliation of the beginning and ending balances of the liabilities: New Fair Value Change in fair Convertible Fair Value April 1, 2016 Value Notes Conversions March 31, 2017 . Notes payable at fair value $ 31,689 $ 3,311 $ $ (35,000 ) $ (M) Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion features. (N) Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model. (0) Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid in capital) and amortized to interest expense over the life of the debt. (P) Debt Issue Costs and Debt Discount The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity (such as warrants). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed. (Q) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. Pursuant to ASC paragraph 505-50-30-S99-1, if the Company receives a right to receive future services in exchange for unvested, forfeitable equity instruments, those equity instruments are treated as unissued for accounting purposes until the future services are received (that is, the instruments are not considered issued until they vest). Consequently, there would be no recognition at the measurement date and no entry should be recorded. (R) Recent Accounting Pronouncements The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The company will adopt the guidance on January 1, 2018 and apply the cumulative catch-up transition method. The transition adjustment to be recorded to stockholders’ equity upon adoption of the new standard is not expected to be material. All newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Derivative Liability_Notes Paya

Derivative Liability/Notes Payable Convertible Debentures	12 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Derivative Liability/Notes Payable Convertible Debentures	NOTE 2 DERIVATIVE LIABILITY/NOTES PAYABLE CONVERTIBLE DEBENTURES In April of 2016 the Company paid a convertible debenture in full for $35,000. The Company has one sole convertible note in the amount of $105,000. The maturity date of the convertible note is February 21, 2018 with an interest rate of 12% per annum. Interest will be payable on the maturity date in cash, unless the note is converted earlier. In July 2016, the Company recognized a gain on the settlement of derivative liability of $24,460.

Related Party Payable

Related Party Payable	12 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Payable	NOTE 3 RELATED PARTY PAYABLE At March 31, 2017, the Company is obligated for unpaid officer salaries and advances of $197,055 that consist of $5,915 in accounts payable due to officers, $94,188 in bridge loan and other loans made by officers to the Company, and accrued interest on loans of $16,952.

Note Payable and Line of Credit

Note Payable and Line of Credit	12 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Note Payable and Line of Credit	NOTE 4 NOTE PAYABLE AND LINE OF CREDIT The Company is obligated on the following notes: 1. Third Party Individuals 67,826 2. Bank Credit Line * 63,421 Total $ 131,247 *As of November 26, 2017, Gel-Del Technologies, Inc. was delinquent in the monthly payments of the Bank Credit Line and a Bank Credit Card through the same banking institution. The Company negotiated a settlement with the bank regarding the Bank Credit Line having an outstanding balance of $50,000 and the Bank Credit Card having an outstanding balance of $10,000; both were originally incurred by Gel-Del Technologies, Inc. The bank agreed to a settlement payment of $38,000 for the combined balance of $60,000. A payment plan of $8,000 due on September 29, 2017 to be applied to the Bank Credit Line in the amount of $6,666 and $1,333 applied to the credit card balance. A payment of $10,000 due on October 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A payment of $10,000 due on November 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A final payment of $10,000 due on December 15, 2017 to be applied to the Bank Credit Line in the amount of $8,333 and $1,666 applied to the credit card balance. The Company has a bank credit line of $75,000. At March 31, 2017 there was $11,579 of unused credit. Interest is at 6.5%. As mentioned above, as of December 15, 2017, the Company plans to complete the payment plan with Wells Fargo Bank. The Company was indebted on a note bearing interest at prime plus 5.5% to a bank with a monthly payment of $2,786 and expiring in January, 2017. All assets of Gel-Del are pledged as collateral. On February 23, 2017, the Company paid this note in full and received a release of the collateral pledge in all assets of Gel-Del. The Company is indebted to Robert Rudelius in the amount of $55,326 which consists of a convertible note of $50,000 and accrued interest of $5,326. The interest rate on this loan is 8%. The Company is indebted to Scott Johnson in the amount of $7,500. The interest rate on this loan is 6% and a due date of September 2, 2018. The Company is indebted to Gary Bryant in the amount of $5,000. The interest rate on this loan is 6% and a due date of December 14, 2018.

Going Concern

Going Concern	12 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 5–GOING CONCERN As reflected in the accompanying financial statements, the Company had minimal revenue and had a negative equity and a material loss. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is in the process of securing an underwriter to raise funds commencing the first quarter of 2018 in order to fund future operations. At the present time the Company has sufficient funds to begin operations with a recent move into new office space which houses laboratories for the commencement of KUSH products. The new laboratories are being set up to begin production in the first quarter 2018. The Company has secured sales and marketing teams to sell product once production commences. The Company added new independent board members and has formed a business advisory committee. Other board committees are in the process of being formed as well. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in the viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate funds. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Common Stock

Common Stock	12 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Common Stock	NOTE 6– COMMON STOCK The Company issued 95,100 shares of common stock in the quarter ended June 30, 2015, of which 14,000 shares were for services valued at market for $56,000. 70,500 shares were issued for debt reduction of $282,000 and 10,600 shares for cash of $37,100. From July 1, 2015 to September 30, 2015 the Company issued 1,250 shares for an extension of a convertible debt consideration valued at market for an expense of $4,350. From October 1, 2015 to December 31, 2015 the Company issued 125,000 shares of stock for services valued at market which equaled $474,500. Some of the services are recognized over a one year contract with the unearned portion shown as prepaid expense. From January 1 to March 31, 2016 10,000 shares were issued for services of $24,750. In March 2016 the Company agreed to settle their convertible debt with interest by issuing 788,325 shares at $2.00 per share. The actual shares issuance occurred in April 2016. Also during this period the Company received $100,000 for stock in its subsidiary pursuant to a subscription agreement. From April 1, 2016 to June 30, 2016 the Company granted 953,142 shares of which 788,325 were issued to satisfy debt of $1,575,649, 40,000 shares for cash of $60,000 and the remainder of 124,817 shares were issued as follows; 27,475 for services valued at market for $42,500 and 97,342 shares for interest valued at $151,476. From July 1, 2016 to September 30, 2016, the Company issued 136,500 shares of common stock in the quarter ended September 30, 2016, of which 110,000 shares were for services valued at market for $190,000, and 26,500 shares for cash of $39,750. The Company received cash of $60,000 for 60,000 shares to be issued. From October 1, 2016 to December 31, 2016, the Company issued -0- shares of common stock in the quarter ended December 31, 2016, of which -0- shares were for services valued at market for $-0-, and -0- shares for cash of $-0-. Warrants were issued for services valued at $134,400. From January 1, 2017 to March 31, 2017, the Company issued 300,000- shares of common stock in the quarter ended March 31, 2017, of which 300,000 shares were for services valued at market for $150,000, and -0- shares for cash of $-0-.The Company agreed to issue stock for accrued officer salaries due from PetVivo, Inc. and Gel-Del Technologies, Inc. valued at $1,209,919. The Company agreed to issue stock for it Chief Revenue Officer valued at $80,000. The Company issued stock for services of employees of Gel-Del valued at $12,859. As of March 31, 2017, the Company had 133,250 warrants outstanding.

Agreement and Plan of Merger

Agreement and Plan of Merger	12 Months Ended
	Mar. 31, 2017
Agreement And Plan Of Merger
Agreement and Plan of Merger	NOTE 7 - AGREEMENT AND PLAN OF MERGER The Agreement and Plan of Merger was completed by the Company’s wholly-owned subsidiary, PetVivo Holdings Newco Inc. (“Newco”) and Gel-Del (the “Merger Agreement”). In accordance with the terms and provisions of the Merger Agreement, the Company effected a statutory merger transaction resulting in an exchange by the shareholders of Gel-Del on a pro rata basis of 100% of all outstanding Gel-Del capital stock in exchange for 5,540,000 shares of the Company’s restricted common stock, which represented approximately 30% of the total issued and outstanding shares of our common stock post-merger. On April 10, 2017, the Merger Agreement was consummated and the Company completed the acquisition of the total issued and outstanding shares of common stock of Gel-Del from the Gel-Del shareholders. The acquisition was completed and consummated through a statutory merger between Gel-Del and NewCo, which resulted in Gel-Del being the surviving entity and becoming our wholly-owned subsidiary. The Merger Agreement became effective upon the filing with the Secretary of State of Minnesota on April 10, 2017. Upon the effectiveness of the Merger Agreement, each share of Gel-Del common stock issued and outstanding immediately prior to the consummation of the Merger Agreement was converted into the right to receive 0.788 common share of the Company. Gel-Del did not have any outstanding options, warrants or other derivative securities or rights convertible into securities. Through this Merger Agreement, we acquired all of Gel-Del’s technology and related patents and other intellectual property (IP) and production techniques, as well as Gel-Del’s modern and secure biomedical product manufacturing facilities being jointly constructed by Gel-Del and the Company in Edina, Minnesota. Although the Agreement and Plan of Merger had been completed, the shares of common stock were issued September 5, 2017.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 INCOME TAXES The following table presents the current and deferred income tax provision (benefit) for federal and state income taxes: 2017 2016 Current tax provision: Federal $ – $ – State – – Deferred tax provision (benefit): Federal (4,986,791 ) (478,315 ) State (948,664 ) (90,992 ) Change in valuation allowance 5,935,455 569,757 Total provision for income tax $ – $ – Current income taxes are based upon the year’s income taxable for federal and state tax reporting purposes. Deferred income taxes (benefits) are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. Deferred tax assets and liabilities are computed for differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the period in which the differences are expected to affect taxable income. The Company’s deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers would be limited under the Internal Revenue Code should a significant change in ownership occur within a three year period. There were no depreciation differences. At March 31, 2017 and 2016, the Company had net operating loss carryforwards of approximately $16,762,992 and $2,095,960, respectively, which begin to expire in 2029. The deferred tax assets arising from the net operating loss carryforwards are approximately $16,763,000 and $789,000 as of March 31, 2017 and 2016, respectively. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, the projected future taxable income and tax planning strategies in making this assessment. Based on management’s analysis, they concluded not to retain a deferred tax asset since it is uncertain whether the Company can utilize this asset in future periods. Therefore, they have established a full reserve against this asset. The change in the valuation allowance in 2017 and 2016 was approximately $5,519,204and $90,992 respectively. A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total benefit for income taxes at March 31, 2017, 2016 is as follows: 2017 2016 Expected tax at 34% and 9.3% $ (5,935,455 ) $ (569,307 ) Change in valuation allowance 5,935,455 569,307 Provision for income taxes $ – $ – The Company’s continuing practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of March 31, 2017 and 2016, the Company had no accrued interest and penalties related to uncertain tax positions. The Company is subject to taxation in the U.S. and Minnesota. Our tax years for 02014 and forward are subject to examination by tax authorities. The Company is not currently under examination by any tax authority. Management has evaluated tax positions in accordance with FASB ASC 740, and has not identified any tax positions, other than those discussed above, that require disclosure The Company has not filed tax returns for 2014, 2015, 2016, and 2017. The Company’s subsidiaries, Gel-Del Technologies, Inc., and Cosmeta Corp have not filed tax returns for tax years 2013, 2014, 2015, 2016, and 2017. It should be noted that the tax liability for all the companies for those years is likely to be none or minimal as a result of net operating losses recorded in those years. Gel-Del Technologies, Inc. and Cosmeta Corp file consolidated returns. There are penalties for not filing timely returns. These penalties have not been determined at this time, however, due to the operating losses, penalties are expected to be minimal.

Commitments

Commitments	12 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 9 COMMITMENTS The Company has a month to month lease agreement for manufacturing and office space with a monthly amount of $4,101. During 2017 the rent expense was $130,164 and $134,752 for 2016.

Retirement and Pension Plan

Retirement and Pension Plan	12 Months Ended
	Mar. 31, 2017
Retirement Benefits [Abstract]
Retirement and Pension Plan	NOTE 10 RETIREMENT AND PENSION PLAN The Company has instituted a Simplified Employment Pension Plan whereby the employer can contribute up to 15% of salary to a maximum of $22,500 per year. The Company has not paid into the Simplified Employment Pension Plan for fiscal years 2017 and 2016.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 – SUBSEQUENT EVENTS Effective March 8, 2017, John Lai and John Dolan each agreed to cash settlements of $43,625 for $174,500 of their past due compensation, which was subsequently converted into a total of 1,308,750 restricted shares of PetVivo Holdings common stock. Regarding John Lai, his converted shares were offset and reduced by 500,000 shares incident to a former escrow arrangement, resulting in Mr. Lai receiving 154,375 shares through this transaction. David Masters agreed to a cash settlement of $45,592 for $455,919 of his past due compensation and subsequently converted the cash settlement into 683,878 shares. Randall Meyer agreed to a cash settlement of $40,500 for $405,000 of his past due compensation and subsequently converted the cash settlement into 607,500 shares. All of the foregoing securities issuances were unregistered and made by the Company as non-public transactions, and accordingly exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended. On April 10, 2017, Upon the effectiveness of the Merger, each share of Gel-Del common stock outstanding immediately prior to the effective time of the Merger was converted into the right to receive 0.788 common share of the Company. Gel-Del had no outstanding options, warrants or other derivative securities or rights convertible into its securities. As a result of the Merger, the Company issued a total of 5,450,000 shares of its unregistered common stock to the pre-merger shareholders of Gel-Del common stock. The issuance of these shares of common stock of PetVivo is unregistered in reliance upon an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. Effective April 10, 2017, On April 10 2017, On June 26, 2017 David Masters agreed to an adjusted cash settlement of $30,750 for $307,500 of his past due compensation and subsequently converted the adjusted cash settlement into 461,250 shares. Randall Meyer agreed to an adjusted cash settlement of $30,750 for $307,500 of his past due compensation and subsequently converted the adjusted cash settlement into 461,250 shares. John F. Dolan agreed to an adjusted cash settlement of $33,068 for $132,274 of his past due compensation and subsequently converted the adjusted cash settlement into 496,028 shares. John Lai agreed to a cash settlement of $29,979 for $119,918 of his past due compensation and subsequently converted the adjusted cash settlement into 449,692 shares. Effective July 17, 2017 Effective September 5, 2017, On November 28, 2017

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Organization (Policies)	12 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	(A) Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. PetVivo Inc. was originally incorporated under the laws of the state of Minnesota on August 1, 2013.The financials are the result of a merger between Technologies Scan Corp., a corporation incorporated in the State of Nevada on March 31, 2009 now known as PetVivo Holdings, Inc. and its subsidiaries, PetVivo Inc., Gel-Del Technologies, Inc., and Cosmeta Corp. (collectively the “Company”). For accounting purposes the Company is treating the merger as a reverse merger whereby the consolidated financials presented are those of the surviving entity that, which is PetVivo. The merger occurred on March 14, 2014. PetVivo is in the business of distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals. On April 10, 2015 the Company agreed to acquire Gel-Del Technologies. The Company consummated the merger with Gel-Del Technologies, Inc. on April 10, 2017 through an Agreement and Plan of Merger as explained in Note 7. The issuance of the shares to complete the transaction has been finalized and the financials presented are those of the consolidated entities under common control.
Principles of Consolidation	(B) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of PetVivo Holdings, Inc. and its wholly owned operating subsidiary, PetVivo Inc. as well as its variable interest entity (VIE) Gel-Del Technologies and its subsidiary Cosmeta Inc. All intercompany accounts have been eliminated upon consolidation. The consolidation including the VIE is included due to the fact that the Company controls the entity as well as the fact an agreement for acquisition has occurred. The accounting for the acquisition of Gel-Del Technologies on April 10, 2017 was as follows: The Company will issue 5,450,000 shares valued at market at $0.40 per share, which equaled $2,180,000 on the date of closing. The assets of Gel-Del equaled $295,716 and its liabilities were $2,295,462 or a difference of $1,999,746 that resulted in a total purchase consideration of $4,179,746, which was allocated between goodwill and the value of patents & trademarks.
Use of Estimates	(C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(D) Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2017 and March 31, 2016, the Company had no cash equivalents.
Concentration-risk	(E) Concentration-Risk The Company maintains its cash with various financial institutions, which may exceed federally insured limits throughout the period.
Machinery & Equipment	(F) Machinery & Equipment Machinery and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of furniture fixtures and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful life of three (3) years for equipment, five (5) years for automobile, and seven (7) years for furniture and fixtures. Upon sale or retirement of computer equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
Patents and Trademarks	(G) Patents and Trademarks The Company capitalizes direct costs for their maintenance and advancement of their patents and trademarks and amortizes these costs over a useful life of 60 months.
Income Taxes	(H) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company adopted the provisions of ASC Topic 740, on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with Statement of Financial Accounting Standards No. 5, Accounting for Contingencies. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Loss Per Share	(I) Loss Per Share In accordance with the accounting guidance now codified as FASB ASC Topic 260, “Earnings per Share” basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period.
Revenue Recognition	(J) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 605, “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. Revenues consist of Kush product sales to veterinary clinics.
Research and Development	(K) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(L) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts payable, accrued expenses, notes payable, notes payable - related party, loan payable - related party and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of March 31, 2017 and March 31, 2016, due to the short-term nature of these instruments. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The following table represents the Company’s assets and liabilities by level measured at fair value on a recurring basis at March 31, 2017: Description Level 1 Level 2 Level 3 Notes payable at fair value $ $ $ The following assets and liabilities are measured on the condensed consolidated balance sheets at fair value on a recurring basis utilizing significant unobservable inputs or Level 3 assumptions in their valuation. The following tables provide a reconciliation of the beginning and ending balances of the liabilities: New Fair Value Change in fair Convertible Fair Value April 1, 2016 Value Notes Conversions March 31, 2017 . Notes payable at fair value $ 31,689 $ 3,311 $ $ (35,000 ) $
Embedded Conversion Features	(M) Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion features.
Derivative Financial Instruments	(N) Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
Beneficial Conversion Feature	(0) Beneficial Conversion Feature For conventional convertible debt where the rate of conversion is below market value, the Company records a “beneficial conversion feature” (“BCF”) and related debt discount. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid in capital) and amortized to interest expense over the life of the debt.
Debt Issue Costs and Debt Discount	(P) Debt Issue Costs and Debt Discount The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity (such as warrants). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.
Stock-based Compensation - Non-employees	(Q) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. Pursuant to ASC paragraph 505-50-30-S99-1, if the Company receives a right to receive future services in exchange for unvested, forfeitable equity instruments, those equity instruments are treated as unissued for accounting purposes until the future services are received (that is, the instruments are not considered issued until they vest). Consequently, there would be no recognition at the measurement date and no entry should be recorded.
Recent Accounting Pronouncements	(R) Recent Accounting Pronouncements The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The company will adopt the guidance on January 1, 2018 and apply the cumulative catch-up transition method. The transition adjustment to be recorded to stockholders’ equity upon adoption of the new standard is not expected to be material. All newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Organization (Tables)	12 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured On Recurring Basis	The following table represents the Company’s assets and liabilities by level measured at fair value on a recurring basis at March 31, 2017: Description Level 1 Level 2 Level 3 Notes payable at fair value $ $ $
Schedule of Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation	The following tables provide a reconciliation of the beginning and ending balances of the liabilities: New Fair Value Change in fair Convertible Fair Value April 1, 2016 Value Notes Conversions March 31, 2017 . Notes payable at fair value $ 31,689 $ 3,311 $ $ (35,000 ) $

Note Payable and Line of Cred_2

Note Payable and Line of Credit (Tables)	12 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Summary of Note Payable and Line of Credit	The Company is obligated on the following notes: 1. Third Party Individuals 67,826 2. Bank Credit Line * 63,421 Total $ 131,247 *As of November 26, 2017, Gel-Del Technologies, Inc. was delinquent in the monthly payments of the Bank Credit Line and a Bank Credit Card through the same banking institution. The Company negotiated a settlement with the bank regarding the Bank Credit Line having an outstanding balance of $50,000 and the Bank Credit Card having an outstanding balance of $10,000; both were originally incurred by Gel-Del Technologies, Inc. The bank agreed to a settlement payment of $38,000 for the combined balance of $60,000. A payment plan of $8,000 due on September 29, 2017 to be applied to the Bank Credit Line in the amount of $6,666 and $1,333 applied to the credit card balance. A payment of $10,000 due on October 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A payment of $10,000 due on November 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A final payment of $10,000 due on December 15, 2017 to be applied to the Bank Credit Line in the amount of $8,333 and $1,666 applied to the credit card balance.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Income Tax Provision (Benefit)	The following table presents the current and deferred income tax provision (benefit) for federal and state income taxes: 2017 2016 Current tax provision: Federal $ – $ – State – – Deferred tax provision (benefit): Federal (4,986,791 ) (478,315 ) State (948,664 ) (90,992 ) Change in valuation allowance 5,935,455 569,757 Total provision for income tax $ – $ –
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the expected tax computed at the U.S. statutory federal income tax rate to the total benefit for income taxes at March 31, 2017, 2016 is as follows: 2017 2016 Expected tax at 34% and 9.3% $ (5,935,455 ) $ (569,307 ) Change in valuation allowance 5,935,455 569,307 Provision for income taxes $ – $ –

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Apr. 10, 2017	Mar. 31, 2017
Patents And Trademarks [Member]
Estimated useful life of assets		60 months
Equipment [Member]
Estimated useful life of assets		3 years
Automobiles [Member]
Estimated useful life of assets		5 years
Furniture and Fixtures [Member]
Estimated useful life of assets		7 years
Gel-Del Technologies [Member]
Number of shares issued during period	5,450,000
Market price per share	$ 0.40
Issued shares equaled value	$ 2,180,000
Assets		$ 295,716
Liabilities		2,295,462
Total purchase consideration		1,999,746
Purchase consideration allocated to goodwill and patents		4,179,746
Cash equivalents

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Organization - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Level 1 [Member]
Notes payable at fair value
Level 2 [Member]
Notes payable at fair value
Level 3 [Member]
Notes payable at fair value		$ 31,689

Summary of Significant Accoun_6

Summary of Significant Accounting Policies and Organization - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
New Convertible Notes		$ 105,000	$ 524,750
Conversions	$ (35,000)
Level 3 [Member]
Notes Payable at Fair Value, Beginning Balance	$ 31,689	31,689
Change in Fair Value		3,311
New Convertible Notes
Conversions		(35,000)
Notes Payable at Fair Value, Ending Balance			$ 31,689

Derivative Liability_Notes Pa_2

Derivative Liability/Notes Payable Convertible Debentures (Details Narrative) - USD ($)	1 Months Ended
	Jul. 31, 2016	Apr. 30, 2016	Mar. 31, 2017	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible debenture paid		$ 35,000
Convertible note face amount		$ 105,000	$ 105,000	$ 31,689
Convertible note, maturity date		Feb. 21, 2018
Convertible note interest rate		12.00%
Gain on settlement of derivative liability	$ 24,460

Related Party Payable (Details

Related Party Payable (Details Narrative)	Mar. 31, 2017USD ($)
Related Party Transactions [Abstract]
Officer salaries and advances unpaid	$ 197,055
Accounts payable due to officers	5,915
Bridge loan and other loans	94,188
Accrued interest on loans	$ 16,952

Note Payable and Line of Cred_3

Note Payable and Line of Credit (Details Narrative)	Mar. 31, 2017USD ($)	Mar. 31, 2017USD ($)
Line of credit, outstanding balance	$ 75,000	$ 75,000
Unused credit	$ 11,579
Interest rate	6.50%
Note bearing interest	5.50%	5.50%
Monthly payment to bank	$ 2,786
Loan maturity date	Jan. 31, 2017
Robert Rudelius [Member]
Interest rate		8.00%
Robert Rudelius [Member]
Indebted amount	$ 55,326	$ 55,326
Convertible note	50,000	50,000
Accrued interest	5,326	$ 5,326
Scott Johnson [Member]
Interest rate		6.00%
Loan maturity date		Sep. 2, 2018
Indebted amount	7,500	$ 7,500
Gary Bryant [Member]
Interest rate		6.00%
Loan maturity date		Dec. 14, 2018
Indebted amount	$ 5,000	$ 5,000

Note Payable and Line of Cred_4

Note Payable and Line of Credit - Summary of Note Payable and Line of Credit (Details) - USD ($)		Mar. 31, 2017	Mar. 31, 2016
Debt Disclosure [Abstract]
Third Party Individuals		$ 67,826
Bank Credit Line	[1]	63,421
Total		$ 131,247	$ 165,849
[1]	As of November 26, 2017, Gel-Del Technologies, Inc. was delinquent in the monthly payments of the Bank Credit Line and a Bank Credit Card through the same banking institution. The Company negotiated a settlement with the bank regarding the Bank Credit Line having an outstanding balance of $50,000 and the Bank Credit Card having an outstanding balance of $10,000; both were originally incurred by Gel-Del Technologies, Inc. The bank agreed to a settlement payment of $38,000 for the combined balance of $60,000. A payment plan of $8,000 due on September 29, 2017 to be applied to the Bank Credit Line in the amount of $6,666 and $1,333 applied to the credit card balance. A payment of $10,000 due on October 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A payment of $10,000 due on November 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A final payment of $10,000 due on December 15, 2017 to be applied to the Bank Credit Line in the amount of $8,333 and $1,666 applied to the credit card balance.

Note Payable and Line of Cred_5

Note Payable and Line of Credit - Summary of Note Payable and Line of Credit (Details) (Parenthetical)	Mar. 31, 2017USD ($)		Mar. 31, 2017USD ($)
Line of credit, outstanding balance	$ 75,000		$ 75,000
Payment plan due	$ 63,421	[1]	63,421	[1]
Line of credit due date	Jan. 31, 2017
Due on September 29, 2017 [Member]
Settlement payment	$ 38,000		38,000
Line of credit combined balance	60,000		60,000
Payment plan due	8,000		$ 8,000
Line of credit due date			Sep. 29, 2017
Bank credit line, amount	6,666		$ 6,666
Credit card balance	1,333		1,333
Due on October 15 2017 [Member]
Payment plan due	10,000		$ 10,000
Line of credit due date			Oct. 15, 2017
Bank credit line, amount	8,333		$ 8,333
Due on November 15 2017 [Member]
Payment plan due	10,000		$ 10,000
Line of credit due date			Nov. 15, 2017
Bank credit line, amount	8,333		$ 8,333
Credit card balance	1,666		1,666
Due on December 15 2017 [Member]
Payment plan due	10,000		$ 10,000
Line of credit due date			Dec. 15, 2017
Bank credit line, amount	8,333		$ 8,333
Credit card balance	1,666		1,666
Bank Credit Line [Member]
Line of credit, outstanding balance	50,000		50,000
Bank Credit Card [Member]
Line of credit, outstanding balance	$ 10,000		$ 10,000
[1]	As of November 26, 2017, Gel-Del Technologies, Inc. was delinquent in the monthly payments of the Bank Credit Line and a Bank Credit Card through the same banking institution. The Company negotiated a settlement with the bank regarding the Bank Credit Line having an outstanding balance of $50,000 and the Bank Credit Card having an outstanding balance of $10,000; both were originally incurred by Gel-Del Technologies, Inc. The bank agreed to a settlement payment of $38,000 for the combined balance of $60,000. A payment plan of $8,000 due on September 29, 2017 to be applied to the Bank Credit Line in the amount of $6,666 and $1,333 applied to the credit card balance. A payment of $10,000 due on October 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A payment of $10,000 due on November 15, 2017 to be applied to the Bank Credit Line in the amount of $ 8,333 and $1,666 applied to the credit card balance. A final payment of $10,000 due on December 15, 2017 to be applied to the Bank Credit Line in the amount of $8,333 and $1,666 applied to the credit card balance.

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2017	Mar. 31, 2016
Number of shares issued during period	300,000	0	136,500	953,142				95,100
Number of shares issued during period for services	300,000	0	110,000	27,475	10,000	125,000		14,000
Number of shares issued during period for services, value	$ 150,000	$ 0	$ 190,000	$ 42,500	$ 24,750	$ 474,500		$ 56,000	$ 382,500	$ 555,250
Shares issued for debt reduction								70,500
Shares issued for debt reduction, value								$ 282,000
Number of shares issued during period for cash	0	0	26,500	40,000				10,600
Number of shares issued during period for cash, value	$ 0	$ 0	$ 39,750	$ 60,000				$ 37,100	1,349,919
Shares issued for convertible debt							1,250
Shares issued for convertible debt, value							$ 4,350			$ 1,576,649
Shares issued for settlement of convertible debt				788,325	788,325
Shares issued price per share					$ 2					$ 2
Remainder of shares issued				124,817
Proceeds from issuance of common stock			$ 60,000						99,750	$ 137,105
Shares issued for settlement of convertible debt, value				$ 1,575,649
Shares issued for interest				97,432
Shares issued for interest, value				$ 151,476
Common stock shares to be issued			60,000
Shares issuable against settlement	$ 1,209,919								$ 1,209,919
Warrants outstanding	133,250								133,250
Chief Revenue Officer [Member]
Number of shares issued during period	80,000
Employees [Member]
Number of shares issued during period for services	12,859
Warrant [Member]
Number of shares issued during period for services, value		$ 134,400
Subscription Agreement [Member]
Proceeds from issuance of common stock					$ 100,000

Agreement and Plan of Merger (D

Agreement and Plan of Merger (Details Narrative)	12 Months Ended
	Mar. 31, 2017shares
Agreement And Plan Of Merger
Pro rata basis outstanding, percentage	100.00%
Capital stock exchanged for restricted common stock	5,540,000
Acquisition of common stock issued and outstanding, percentage	30.00%
Merger agreement converted, description	Merger Agreement was converted into the right to receive 0.788 common share of the Company.

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 16,762,992	$ 2,095,960
Operating loss carryforward expiration date description	Expire in 2029
Deferred tax assets	$ 16,763,000	789,000
Net operating loss carry forwards expire	Begin to expire in 2029
Change in the valuation allowance	$ 5,519,204	90,992
Accrued interest and penalties related to uncertain tax positions

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Current, Federal
Current, State
Deferred, Federal	(4,986,791)	(478,315)
Deferred, State	(948,664)	(90,992)
Change in valuation allowance	5,935,455	569,757
Total provision for income tax

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Expected tax at 34 and 9.3%	$ (5,935,455)	$ (569,307)
Change in valuation allowance	5,935,455	569,307
Provision for income taxes

Income Taxes - Schedule of Ef_2

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Effective tax rate, percentage	34.00%	9.30%

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Lease monthly amount	$ 4,101
Rent expense	$ 130,164	$ 134,752

Retirement and Pension Plan (De

Retirement and Pension Plan (Details Narrative) - Simplified Employment Pension Plan [Member]	12 Months Ended
	Mar. 31, 2017USD ($)
Employer contribution of pension plan, percentage	15.00%
Employer contribution of pension plan, amount	$ 22,500

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 28, 2017	Sep. 05, 2017	Jul. 17, 2017	Jun. 26, 2017	Apr. 10, 2017	Mar. 08, 2017	Mar. 31, 2017	Mar. 31, 2016
Merger agreement converted, description							Merger Agreement was converted into the right to receive 0.788 common share of the Company.
Capital stock exchanged for restricted common stock							5,540,000
Business acquisition impairment of goodwill								$ 13,407,693
Trademarks and patents net							1,862,301	$ 3,245,662
Four Officers or Directors Member
Cash settlements in lieu						$ 1,209,919
Four Officers or Directors Member | Restricted Stock [Member]
Cash settlement converted into restricted share						2,100,128
John Lai [Member]
Cash settlements in lieu							$ 43,625
Common stock shares issuable reduced due to escrow arrangement							500,000
Number of shares receiving through transaction							154,375
John F. Dolan [Member]
Cash settlements in lieu							$ 43,625
John Lai and John Dolan [Member] | Past Due Compensation [Member]
Cash settlements in lieu							$ 174,500
Cash settlement converted into restricted share							1,308,750
David Masters [Member]
Cash settlements in lieu							$ 45,592
David Masters [Member] | Past Due Compensation [Member]
Cash settlements in lieu							$ 455,919
Cash settlement converted into restricted share							683,878
Randall Meyer [Member]
Cash settlements in lieu							$ 40,500
Randall Meyer [Member] | Past Due Compensation [Member]
Cash settlements in lieu							$ 405,000
Cash settlement converted into restricted share							607,500
Subsequent Event [Member]
Realized loss					$ 14,081,031
Capital stock exchanged for restricted common stock					5,450,000
Business acquisition, exercise price					$ 0.40
Capital stock exchanged for common stock, value					$ 2,180,000
Business acquisition impairment of goodwill					13,407,693
Trademarks and patents net					673,340
Subsequent Event [Member] | July 7, 2017 Private Offering [Member]
Proceeds from private offering	$ 516,250
Purchase warrants price per unit	$ 0.35
Subsequent Event [Member] | Gel Del Technologies Inc [Member]
Number of shares issued for replacement		6,856,111
Number of shares replaced		8,589,037
Subsequent Event [Member] | Originally Recorded Securities [Member]
Capital stock exchanged for common stock, value					$ 16,600,000
Subsequent Event [Member] | John Lai [Member]
Settlement acquired compensation due				$ 29,979
Subsequent Event [Member] | John Lai [Member] | Past Due Compensation [Member]
Settlement acquired compensation due				$ 119,918
Settlement acquired compensation due, shares				449,692
Subsequent Event [Member] | John F. Dolan [Member]
Settlement acquired compensation due				$ 33,068
Subsequent Event [Member] | John F. Dolan [Member] | Past Due Compensation [Member]
Settlement acquired compensation due				$ 132,274
Settlement acquired compensation due, shares				496,028
Subsequent Event [Member] | David Masters [Member]
Settlement acquired compensation due				$ 30,750
Subsequent Event [Member] | David Masters [Member] | Past Due Compensation [Member]
Settlement acquired compensation due				$ 307,500
Settlement acquired compensation due, shares				461,250
Subsequent Event [Member] | Randall Meyer [Member]
Settlement acquired compensation due				$ 30,750
Subsequent Event [Member] | Randall Meyer [Member] | Past Due Compensation [Member]
Settlement acquired compensation due				$ 307,500
Settlement acquired compensation due, shares				461,250
Subsequent Event [Member] | Four Officers [Member]
Cash settlement converted into restricted share				2,100,128
Subsequent Event [Member] | Mr. Hayne [Member]
Base salary received monthly			$ 8,000
Payment for monthly salary			2,500
Officers compensation periodic payment			5,500
Minimum capital fund amount			$ 1,000,000
Number of restricted common stock granted			200,000
Number of common stock shares assigned			1,250,000
Number of shares acquired upon commencement			50,000
Number of shares escrowed			1,200,000
Subsequent Event [Member] | Mr. Hayne [Member] | Minimum [Member]
Officers compensation periodic payment			$ 96,000